LEADER 00000cam a2200673 a 4500 
001    ocn801916879 
003    OCoLC 
005    20190712071343.4 
006    m     o  d         
007    cr cn||||||||| 
008    120614s2012    cau     ob    000 0 eng   
016 7  101586328|2DNLM 
019    847890378|a867483850|a903552990 
020    9780833079848 
020    0833079840 
027    RAND/TR-1247-AMGEN 
035    (OCoLC)801916879|z(OCoLC)847890378|z(OCoLC)867483850
       |z(OCoLC)903552990 
037    22573/ctt36svrk|bJSTOR 
040    NLM|beng|epn|cNLM|dKLG|dOCLCF|dRSM|dJSTOR|dYDXCP|dTEF
       |dOCLCQ|dOCLCO|dCUS|dOCLCQ|dLND|dLOA|dNLM|dOCLCO|dICG|dU3W
       |dERL|dOCLCA 
042    pcc 
043    e------ 
049    RIDW 
050  4 RC931.O73|b.P68 2012 
082 04 616.7/16|223 
090    RC931.O73|b.P68 2012 
245 00 Postmanopausal osteoporosis management :|ba review of the 
       evidence to inform the development of quality indicators /
       |cAnnalijn Conklin [and others] ; prepared for Amgen. 
264  1 Santa Monica, CA :|bRAND Europe,|c2012. 
300    1 online resource (xv, 110 pages). 
336    text|btxt|2rdacontent 
337    computer|bc|2rdamedia 
338    online resource|bcr|2rdacarrier 
340    |gpolychrome|2rdacc 
347    text file|2rdaft 
490 1  Technical report ;|vTR-1247-AMGEN 
504    Includes bibliographical references. 
505 0  Introduction -- The diagnosis, prevention and treatment of
       postmenopausal osteoporosis -- Managing postmenopausal 
       osteoporosis in Europe -- Informing the development of 
       quality indicators for the management of postmenopausal 
       osteoporosis -- Appendix A: Overview of guidelines in 
       place in four countries -- Appendix B: Interview topic 
       guide. 
520 3  This report aims to inform the development of quality 
       indicators for postmenopausal osteoporosis management 
       through: (a) assessing the evidence for screening and 
       diagnosis of osteoporosis and related risk factors, and 
       for prevention and treatment of osteoporosis and 
       osteoporosis-related fractures; (b) describing current 
       practice for managing postmenopausal osteoporosis in 
       Europe; and (c) highlighting existing gaps in the evidence
       base and management practices in Europe. Analyses involved
       a comprehensive review of reviews regarding the screening 
       and diagnosis of osteoporosis and related risk factors and
       the prevention and treatment of osteoporosis and 
       osteoporosis-related fractures. While this identified a 
       well developed evidence base on the effects of selected 
       treatments on clinical outcomes of postmenopausal 
       osteoporosis and associated fractures, and on the 
       usefulness of selected simple risk factor assessment tools
       to identify postmenopausal women who would benefit from 
       further diagnostic assessment, uncertainties remain 
       regarding for example the optimal use of pharmacological 
       interventions for preventive purposes and the 
       effectiveness of population-based screening. We also 
       carried out case study reviews of current practices for 
       managing postmenopausal osteoporosis in England, France, 
       Germany and Spain. We identify a need for the 
       establishment of routine monitoring systems to enable 
       better understanding of contemporary patterns and trends 
       and identify care gaps in the management of postmenopausal
       osteoporosis and associated fractures. Such analyses are 
       crucial to inform targeted strategies and policies to 
       effectively address the burden of osteoporosis and 
       associated fractures, which is sizable and set to increase
       across Europe. We set out considerations as a starting 
       point for the further development of quality measures for 
       postmenopausal osteoporosis in Europe. 
588 0  Online resource; title from PDF title page (viewed on July
       9, 2012). 
590    JSTOR|bBooks at JSTOR Open Access 
650  0 Osteoporosis in women|0https://id.loc.gov/authorities/
       subjects/sh97008285|zEurope.|0https://id.loc.gov/
       authorities/subjects/sh85045631-781 
650  0 Evidence-based medicine|0https://id.loc.gov/authorities/
       subjects/sh97007984|zEurope.|0https://id.loc.gov/
       authorities/subjects/sh85045631-781 
650  7 Osteoporosis in women.|2fast|0https://id.worldcat.org/fast
       /1048832 
650  7 Evidence-based medicine.|2fast|0https://id.worldcat.org/
       fast/917247 
651  2 Europe.|0https://id.nlm.nih.gov/mesh/D005060 
651  7 Europe.|2fast|0https://id.worldcat.org/fast/1245064 
655  2 Review.|0https://id.nlm.nih.gov/mesh/D016454 
655  4 Electronic books. 
700 1  Conklin, Annalijn.|0https://id.loc.gov/authorities/names/
       n2010184853 
710 2  RAND Europe.|0https://id.loc.gov/authorities/names/
       n97080747 
710 2  Amgen Inc.|0https://id.loc.gov/authorities/names/
       nr94015151 
830  0 Technical report (Rand Corporation) ;|0https://id.loc.gov/
       authorities/names/n2005069635|vTR-1247-AMGEN. 
856 40 |uhttps://www.jstor.org/stable/10.7249/j.ctt3fh1vm|zOnline
       eBook. Open Access via JSTOR. 
901    MARCIVE 20231220 
948    |d20190820|cJSTOR EBSCO|tJSTOROpenAccess 
       EBSCOebooksacademic UPDATES 5472J 1248 BOTH 7-12-19|lridw 
948    |d20180926|clti|tlti-aex 
948    |d20171005|cJSTOR|tJSTOROpenAccess new|lridw 
994    92|bRID